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Repair of the injured spinal cord has been one of the great
quests of experimental neuroscience since Tello and Cajal
first showed in 1903 that axons in the central nervous
system (CNS) can be made to regenerate. Sadly, we have yet
to achieve a treatment that is licensed for this purpose in
human patients, although advances such as that described
by Davies et al. in this issue of the Journal of Biology [1] will
help to bring this goal closer.
One of the earliest concepts in spinal cord repair was to
build a bridge across the injury that would provide a road
along which regenerating axons could cross the injury site
to find suitable targets, form connections and restore
function. This was first attempted by Peter Richardson, Sam
David and Albert Aguayo in 1981 [2,3], when they
implanted grafts of peripheral nerve tissue (which is
permissive to axon regeneration) across a spinal injury.
These experiments demonstrated both the possibilities and
the problems of the bridging concept. Axons regenerated
into the grafts, but only from nearby neurons, and hardly
any of the axons could then leave the attractive environ-
ment of the graft to re-enter CNS tissue. In terms of bridge
design, axons could traverse the on-ramp to get into the
graft and they could grow across the bridge, but they got
stuck on the off-ramp. What was the problem? The first was
that the Schwann cells - the supporting glial cells of the
peripheral nervous system (PNS) - exert a honey-pot effect;
growing axons are very good at selecting pathways and they
will seldom grow from a permissive PNS environment to a
less permissive CNS one. The second was that Schwann cells
will not mix with astrocytes (the CNS glial cells), so a sharp
cellular boundary of astrocytes reacting to the Schwann cells
blocks the off-ramp.
Clearly, if the bridge concept is to work, we need to find a
better type of cell with which to construct the bridge. This
cell type must integrate seamlessly into spinal cord tissue, it
must not stimulate a glial scar reaction and it must
promote axon growth but not be so attractive that axons
cannot pass on into the cord. Various cell types have been
grafted into the spinal cord in the hope that they would
have these properties, one of the most successful being
olfactory ensheathing glia [4]. In this issue of Journal of
Biology, Stephen Davies and co-workers [1] describe a
particular type of immature astrocyte that seems to provide
a very successful bridging material.
The idea of using embryonic CNS tissue and embryonic
astrocytes for repairing the spinal cord has a long history.
Axons grow in the embryonic CNS, so why not transplant
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embryonic spinal cord into injuries? Host axons regenerate
into these transplants, but seldom through them. In the
grafts they can connect to graft neurons, which in turn can
send their axons back into the host cord, the grafts acting as
relays [5]. If embryonic CNS tissue promotes growth, then
transplantation of embryonic glia is a logical next step, and
there are reports going back to 1990 using this strategy to
promote axon regeneration [6].
However, astrocytes are hugely diverse, some types being
permissive to regeneration, others inhibitory. We now know
much more about the various subtypes of glia and their
developmental profiles, so it is possible to be more specific
about which type of glial cell to transplant, and it is this
knowledge that has formed the basis for the work from
Davies and colleagues [1], who used immature glial
precursor cells whose differentiation they manipulated in
vitro. Various types of glial stem cell have been tried in
earlier experiments, with mixed effects in the injured spinal
cord. The transplants may protect the cord from secondary
degeneration after injury and may produce myelinating
cells, but they have not been very effective at promoting
regeneration [7,8]. Indeed, Lars Olson and colleagues [9]
report that stem cell transplants can stimulate sprouting of
sensory axons leading to allodynia - a condition in which
normal sensory stimuli cause pain.
In an earlier paper [10], Stephen Davies and collaborators
reported the identification of a type of immature precursor-
derived astrocyte that provides an excellent building
material for spinal cord bridges, produced by treating glial-
restricted precursors with bone morphogenetic protein
(BMP)-4. The cells migrate into host tissue and mix with
host glia while suppressing scar formation, and they promote
regeneration of sensory axons and improved locomotor
function. It will be interesting to compare these cells with
the radial glial cells transplanted by the Grumet lab, which
also had beneficial effects [11], and to see whether they
promote the regeneration of motor pathways.
Davies and colleagues now report [1] the identification of a
form of astrocyte, derived from exactly the same precursor
population as used previously [10], that integrates poorly,
does not stimulate regeneration or recovery and, worse still,
induces allodynia by increasing sprouting of pain fibers in
the dorsal horn of the spinal cord. These astrocytes were
produced by treating the precursors with ciliary neuro-
trophic factor (CNTF) and have many of the properties of
the ‘type 2’ astrocyte identified in glial cultures. This is
important progress because grafts of embryonic or
undifferentiated cells might be expected to produce both
the good and bad types of astrocyte, and it emphasizes that
small differences between closely related cells can be
associated with very different potentials for CNS repair. In
this context it is interesting that infusing a CNTF-neutralizing
antibody into a spinal cord containing transplanted neural
stem cells reduced scarring and improved the outcome [12].
The finding by Davies and colleagues [1] and in a previous
publication from the Olson lab [9] that a graft of the wrong
type of glial cells can produce allodynia is particularly
worrying. A third or more of spinal injury patients have
intractable and continuous pain following their injury,
which in some cases never responds satisfactorily to treat-
ment. Spinal injury researchers worry that treatments that
promote axon regeneration might also cause sprouting of
pain fibers, making pain worse. Treating the injured spinal
cord with nerve growth factor (NGF) can do this because
pain fibers express the NGF receptor trkA [13], but the
finding that glial transplants can cause a pain syndrome is a
shock. It is not clear from either paper [1,9] why this might
have happened, but Davies and colleagues [1] suggest that
activation of microglia might be involved.
If progenitor-derived astrocytes produced by BMP-4
treatment are the cells we need in spinal cord injuries, how
are we to get them there? In this paper [1] the cells were
derived from spinal cord taken from rats at embryonic day
13.5. Can they be derived from embryonic stem cells, or
from induced pluripotent state cells taken from the patient?
Or are there glial precursors in the injured cord that could
be induced to produce the right cell type? There will also
have to be a decision on whether the progenitor-derived
astrocyte is a more or less effective bridging cell than the
olfactory ensheathing cell. From a practical point of view,
cells derived in some way from individual patients will
avoid the need for immunosuppression. However, such
autologous cells will not be available until some time after
injury, and it will be important to know for how long after
damage the transplants remain effective. Current work has
involved transplantation at the time of injury, which will be
difficult to achieve in human patients.
There are several treatments under development for spinal
cord injury, aimed at various mechanisms, including neutrali-
zation of inhibitory molecules, promotion of plasticity,
direct stimulation of axon regeneration, bridging and
control of inflammation. A combination of two or more of
these approaches will be needed to achieve optimal spinal
cord repair. So far there have been relatively few attempts at
combination treatments, mainly because most of the
individual treatments have not been fully optimized and
because spinal repair experiments involving many experi-
mental groups are very demanding. The work from Davies
and collaborators [1] and other groups in identifying an
optimized cell type for grafting into injuries is very
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welcome, and it should provide a transplant strategy that
can be combined with other treatments.
What do these findings mean for patients with spinal cord
injuries? Unfortunately they do not lead immediately to a
treatment applicable to injured humans. However, grafting
cells into injuries to suppress scarring and provide a bridge
will be an important component of a successful combinatorial
treatment, and the findings reported by Davies and colleagues
[1] bring safe and efficacious grafts appreciably closer.
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